 |
 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 July 2002 | Volume 137 Issue 1 | Pages 25-33
Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent. The antihyperglycemic properties of metformin are mainly attributed to suppressed hepatic glucose production, especially hepatic gluconeogenesis, and increased peripheral tissue insulin sensitivity. Although the precise mechanism of hypoglycemic action of metformin remains unclear, it probably interrupts mitochondrial oxidative processes in the liver and corrects abnormalities of intracellular calcium metabolism in insulin-sensitive tissues (liver, skeletal muscle, and adipocytes) and cardiovascular tissue.
Author and Article Information
From State University of New York Health Science Center at Brooklyn and Veterans Affairs Medical Center, Brooklyn, New York.
Acknowledgments: The authors thank Jun Ren, PhD; Amy Davidoff, PhD; and Jacob Peuler, PhD, for their seminal contribution to work on the cardiovascular effects of metformin.
Grant Support: By the National Institutes of Health (RO1-HL-63904-01), the Veterans Affairs Merit Review, and the American Diabetic Association.
Requests for Single Reprints: James R. Sowers, MD, State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 1205, Brooklyn, NY 11203; e-mail, jsowers{at}netmail.hscbklyn.edu.
Current Author Addresses: Drs. Kirpichnikov, McFarlane, and Sowers: State University of New York Health Science Center at Brooklyn, 450 Clarkson Avenue, Box 1205, Brooklyn, New York 11203. UPDATE
Metformin: An Update
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. Anedda, E. Rial, and M M. Gonzalez-Barroso Metformin induces oxidative stress in white adipocytes and raises uncoupling protein 2 levels J. Endocrinol., October 1, 2008; 199(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Matsumoto, E. Noguchi, K. Ishida, T. Kobayashi, N. Yamada, and K. Kamata Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes Am J Physiol Heart Circ Physiol, September 1, 2008; 295(3): H1165 - H1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hong, S. Rohatagi, B. Habtemariam, J. R. Walker, S. L. Schwartz, and D. E. Mager Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus J. Clin. Pharmacol., June 1, 2008; 48(6): 696 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and the MiG Trial Investigators Metformin versus Insulin for the Treatment of Gestational Diabetes N. Engl. J. Med., May 8, 2008; 358(19): 2003 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Calvert, S. Gundewar, S. Jha, J. J.M. Greer, W. H. Bestermann, R. Tian, and D. J. Lefer Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS-Mediated Signaling Diabetes, March 1, 2008; 57(3): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. D. Kim, K.-G. Park, Y.-S. Lee, Y.-Y. Park, D.-K. Kim, B. Nedumaran, W. G. Jang, W.-J. Cho, J. Ha, I.-K. Lee, et al. Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP Diabetes, February 1, 2008; 57(2): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Odegard, S. M. Setter, and J. J. Neumiller Considerations for the Pharmacological Treatment of Diabetes in Older Adults Diabetes Spectr, October 1, 2007; 20(4): 239 - 247. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rowan and on behalf of the MiG Investigators A Trial in Progress: Gestational Diabetes: Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial) Diabetes Care, July 1, 2007; 30(Supplement_2): S214 - S219. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi Gestational Diabetes After Delivery: Short-term management and long-term risks Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karim, M. Slater, D. Bradford, L. Schwartz, Z. Zhao, C. Cao, and A. Laurent Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed-Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug J. Clin. Pharmacol., January 1, 2007; 47(1): 37 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suwa, T. Egashira, H. Nakano, H. Sasaki, and S. Kumagai Metformin increases the PGC-1{alpha} protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo J Appl Physiol, December 1, 2006; 101(6): 1685 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Koski Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus The Diabetes Educator, November 1, 2006; 32(6): 869 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, M. Molitch, M. K. Kramer, S. Kahn, Y. Ma, S. Edelstein, K. Smith, M. K. Johnson, A. Kitabchi, J. Crandall, et al. Adherence to Preventive Medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, September 1, 2006; 29(9): 1997 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Friesecke, P. Abel, M. Kraft, A. Gerner, and S. Runge Combined renal replacement therapy for severe metformin-induced lactic acidosis Nephrol. Dial. Transplant., July 1, 2006; 21(7): 2038 - 2039. [Full Text] [PDF]
|
|
|
|
|
|
A. Balasubramanyam, D. Hinnen, and W. Polonsky Cardiovascular Event Prevention in the Person With Type 2 Diabetes: Case Examples for Identifying and Treating Multiple Risks The Diabetes Educator, July 1, 2006; 32(Supplement_5): 163S - 173S. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schwartz, V. Fonseca, B. Berner, M. Cramer, Y.-K. Chiang, and A. Lewin Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes Diabetes Care, April 1, 2006; 29(4): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dhahbi, P. L. Mote, G. M. Fahy, and S. R. Spindler Identification of potential caloric restriction mimetics by microarray profiling Physiol Genomics, November 17, 2005; 23(3): 343 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Diabetes Care, May 1, 2005; 28(5): 1083 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1092 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Tushuizen, M Diamant, and R J Heine Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes Postgrad. Med. J., January 1, 2005; 81(951): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes J. Endocrinol., November 1, 2004; 183(2): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marchetti, S. Del Guerra, L. Marselli, R. Lupi, M. Masini, M. Pollera, M. Bugliani, U. Boggi, F. Vistoli, F. Mosca, et al. Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5535 - 5541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Diabetes Care, November 1, 2004; 27(11): 2628 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Caballero, A. Delgado, C. A. Aguilar-Salinas, A. N. Herrera, J. L. Castillo, T. Cabrera, F. J. Gomez-Perez, and J. A. Rull The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3943 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Medina, L. I. Fernandez-Salazar, L. Garcia-Buey, and R. Moreno-Otero Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis Diabetes Care, August 1, 2004; 27(8): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Nylen and B. Muller Endocrine Changes in Critical Illness J Intensive Care Med, March 1, 2004; 19(2): 67 - 82. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Benavides and M. C Nahata Pharmacologic Therapy for HIV-Associated Lipodystrophy Ann. Pharmacother., March 1, 2004; 38(3): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Koski Oral Antidiabetic Agents: A Comparative Review Journal of Pharmacy Practice, February 1, 2004; 17(1): 39 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Wolf and E. Ritz Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1396 - 1405. [Full Text] [PDF]
|
|
|
|
|
|
The Diabetes Prevention Program Research Group Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program Diabetes Care, April 1, 2003; 26(4): 977 - 980. [Abstract] [Full Text] [PDF]
|
|
Article
